AstraZeneca’s Forxiga Secures Chinese Approval for Heart Failure

AstraZeneca’s (AZ) type 2 diabetes drug Forxiga (dapagliflozin) has received regulatory approval in China for treating heart failure with reduced ejection fraction in adults with or without type 2 diabetes.

The drug is now approved in China for reducing the risk of cardiovascular death and hospitalization for patients with the life-threatening condition, which occurs when the heart’s left ventricle muscle cannot properly contract and expels less blood into the body.

AZ’s Forxiga has also earned regulatory approval for the same indication in other countries, including in the U.S., Europe and Japan.